← Eichor
Study identifier: NCT06280508 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Chemotherapy Combined With Adebrelimab and Apatinib as the Perioperative Treatment in Patients With Biliary Tract Cancer

Condition: Resectable Intrahepatic Cholangiocarcinoma With High Risk of Recurrence  ·  Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

PhasePhase 2
Planned participants40
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a prospective, single-arm exploratory study to evaluate the efficacy and safety of chemotherapy combined with Adebrelimab and Apatinib as the perioperative treatment in Patients With Biliary Tract Cancer.

This description comes directly from the study's public registry record.

Talk to the study team

Yajin Chen  ·  13719006202  ·  cyj0509@126.com

Changzhen shang  ·  13711279678  ·  shangchangzhen@139.com

Always discuss trial participation with your own doctor first.

Locations (1)

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityGuangzhou, China/Guangdong, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06280508